secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-041137
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo Q1 FY2024 net loss $2.5M; FDA positive on Phase 3 path for ANEB-001
---------------------------------------------------------------------------

- Net loss of $2.5M ($0.10/sh) vs $2.6M ($0.11/sh) in prior year quarter; operating expenses $2.5M.
- Cash $8.5M as of Sep 30; secured credit facility of up to $10M from existing investors.
- FDA Type B meeting: single ED study plus larger THC challenge may suffice for NDA for ANEB-001.
- Richie Cunningham appointed CEO and Board member; Bimal Shah joined Board; Phase 3 targeted H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223041137/0001493152-23-041137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223041137/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer